2026-04-17T02:46:54Zhttps://recercat.cat/oai/request

oai:recercat.cat:10459.1/4671222025-09-15T18:53:51Zcom_2072_3622col_2072_479130

00925njm 22002777a 4500 dc Meca-Lallana, José E. author Martínez-Yélamos, Sergio author Eichau, Sara author Llaneza, Miguel author Martín Martínez, J. author Meca-Lallana, Virginia author Alonso, Ana author Moral, Ester author Río, Jordi author Calles, Carmen author Ares Luque, A. author Ramió Torrentà, Lluís author Marzo Sola , M. E. author Prieto, J. M. author Martínez Ginés, M. L. author Arroyo, Rafael author Otano Martínez, M. Á. author Brieva Ruiz, Luis author Gómez Gutiérrez, M. author Rodríguez-Antigüedad, Alfredo author Sánchez-Seco, V. G. author Costa-Frossard, Lucienne author Hernández, Miguel Á. author Landete, Lamberto author González Platas, M. author Oreja-Guevara, Celia author 2024 The last consensus statement of the Spanish Society of Neurology’s Demyelinating Diseases Study Group on the treatment of multiple sclerosis (MS) was issued in 2016. Although many of the positions taken remain valid, there have been significant changes in the management and treatment of MS, both due to the approval of new drugs with different action mechanisms and due to the evolution of previously fixed concepts. This has enabled new approaches to specific situations such as pregnancy and vaccination, and the inclusion of new variables in clinical decision-making, such as the early use of high-efficacy disease-modifying therapies (DMT), consideration of the patient’s perspective, and the use of such novel technologies as remote monitoring. In the light of these changes, this updated consensus statement, developed according to the Delphi method, seeks to reflect the new paradigm in the management of patients with MS, based on the available scientific evidence and the clinical expertise of the participants. The most significant recommendations are that immunomodulatory DMT be started in patients with radiologically isolated syndrome with persistent radiological activity, that patient perspectives be considered, and that the term “lines of therapy” no longer be used in the classification of DMTs (> 90% consensus). Following diagnosis of MS, the first DMT should be selected according to the presence/absence of factors of poor prognosis (whether epidemiological, clinical, radiological, or biomarkers) for the occurrence of new relapses or progression of disability; high-efficacy DMTs may be considered from disease onset. Multiple sclerosis Consensus statement Diagnosis Disease-modifying therapy Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023 Documento de consenso de la Sociedad Española de Neurología sobre el tratamiento de la esclerosis múltiple y manejo holístico del paciente 2023